The total return over the past 12 months is +97.61% vs. +16.94% for the S&P 500. So far it's up +84.99% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +97.61% | +67.10% | +47.48% | N/A | N/A | N/A |
| Total Return CAGR | +97.61% | +67.10% | +47.48% | N/A | N/A | N/A |
| Revenue CAGR | +58.85% | +44.12% | +155.66% | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | +99.91% | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | +175.38% | +62.88% | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | +176.68% | +63.37% | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Kiniksa Pharmaceuticals International, plc (KNSA)
| Year | Start price | End price | KNSA Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $41.25 | $76.31 | +84.99% | +14.51% | +70.48% |
| 2025 | $19.78 | $41.25 | +108.54% | +17.72% | +90.82% |
| 2024 | $17.54 | $19.78 | +12.77% | +24.89% | (12.12%) |
| 2023 | $14.98 | $17.54 | +17.09% | +26.19% | (9.10%) |
| 2022 | $11.77 | $14.98 | +27.27% | (18.17%) | +45.44% |
| 2021 | $17.67 | $11.77 | (33.39%) | +28.74% | (62.13%) |
| 2020 | $11.06 | $17.67 | +59.76% | +18.37% | +41.39% |
| 2019 | $28.09 | $11.06 | (60.63%) | +31.22% | (91.85%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
